Max Flogegard

Falun, W, Sweden

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 13 publications

Teclistamab in Multiple Myeloma with One to Three Previous Lines of Therapy.

Teclistamab in Multiple Myeloma with One to Three Previous Lines of Therapy.

Journal: The New England journal of medicine

Published: May 29, 2026

Influence of Cytogenetics on the Outcome of Patients With High-Risk Myelodysplastic Syndrome Including Deletion 5q Treated With Azacitidine With or Without Lenalidomide.

Influence of Cytogenetics on the Outcome of Patients With High-Risk Myelodysplastic Syndrome Including Deletion 5q Treated With Azacitidine With or Without Lenalidomide.

Journal: Genes, chromosomes & cancer

Published: September 05, 2024

Evaluation of coverage, generalisability and validity of the U-CAN lymphoma biobank in Sweden: A comparison with nationwide registers.

Evaluation of coverage, generalisability and validity of the U-CAN lymphoma biobank in Sweden: A comparison with nationwide registers.

Journal: British journal of haematology

Published: June 20, 2024

Spontaneous regression in chronic lymphocytic leukaemia. Clinical features of 50 cases from the ERIC registry and review of the literature.

Spontaneous regression in chronic lymphocytic leukaemia. Clinical features of 50 cases from the ERIC registry and review of the literature.

Journal: British journal of haematology

Published: September 04, 2022

Final analysis of the phase III non-inferiority COLUMBA study of subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma.

Final analysis of the phase III non-inferiority COLUMBA study of subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma.

Journal: Haematologica

Published: June 25, 2021

"Randomized phase II study of azacitidine ± lenalidomide in higher-risk myelodysplastic syndromes and acute myeloid leukemia with a karyotype including Del(5q)".

"Randomized phase II study of azacitidine ± lenalidomide in higher-risk myelodysplastic syndromes and acute myeloid leukemia with a karyotype including Del(5q)".

Journal: Leukemia

Published: May 08, 2021

Age is the most important predictor of survival in diffuse large B-cell lymphoma patients achieving event-free survival at 24 months: a Swedish population-based study.

Age is the most important predictor of survival in diffuse large B-cell lymphoma patients achieving event-free survival at 24 months: a Swedish population-based study.

Journal: British journal of haematology

Published: July 08, 2020

Subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma (COLUMBA): a multicentre, open-label, non-inferiority, randomised, phase 3 trial.

Subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma (COLUMBA): a multicentre, open-label, non-inferiority, randomised, phase 3 trial.

Journal: The Lancet. Haematology

Published: February 04, 2020

Autoimmune disease in patients with diffuse large B-cell lymphoma: occurrence and impact on outcome.

Autoimmune disease in patients with diffuse large B-cell lymphoma: occurrence and impact on outcome.

Journal: Acta oncologica (Stockholm, Sweden)

Published: May 28, 2019

Does the omission of vincristine in patients with diffuse large B cell lymphoma affect treatment outcome?

Does the omission of vincristine in patients with diffuse large B cell lymphoma affect treatment outcome?

Journal: Annals of hematology

Published: June 04, 2018

A genealogical and clinical study of the phenotypical variation within the Swedish transthyretin His88Arg (p. His108Arg) amyloidosis family.

A genealogical and clinical study of the phenotypical variation within the Swedish transthyretin His88Arg (p. His108Arg) amyloidosis family.

Journal: European journal of medical genetics

Published: October 15, 2014

Improved survival in myeloma patients: starting to close in on the gap between elderly patients and a matched normal population.

Improved survival in myeloma patients: starting to close in on the gap between elderly patients and a matched normal population.

Journal: British journal of haematology

Published: May 20, 2013

Showing 1-12 of 13

Last Updated: 09/26/2026